ReviewBioMed research international2014
Novel biomarkers of abdominal aortic aneurysm disease: identifying gaps and dispelling misperceptions.
Review in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Cytokine-Family Biomarker Candidates for Small Abdominal Aortic Aneurysm Identified via Integrated mRNA and Protein Expression Profiling.International journal of molecular sciences · 2026Article
- Dysregulations of Key Regulators of Angiogenesis and Inflammation in Abdominal Aortic Aneurysm.International journal of molecular sciences · 2023Article
- Association of Aneurysm Tissue Neutrophil Mediator Levels with Intraluminal Thrombus Thickness in Patients with Abdominal Aortic Aneurysm.Biomolecules · 2022Article
- Biomarkers in EndoVascular Aneurysm Repair (EVAR) and Abdominal Aortic Aneurysm: Pathophysiology and Clinical Implications.Diagnostics (Basel, Switzerland) · 2022Review
- Identification of key monocytes/macrophages related gene set of the early-stage abdominal aortic aneurysm by integrated bioinformatics analysis and experimental validation.Frontiers in cardiovascular medicine · 2022Article
- Metabolomic Profile of Abdominal Aortic Aneurysm.Metabolites · 2021Article
- Non-Coding RNAs as Blood-Based Biomarkers in Cardiovascular Disease.International journal of molecular sciences · 2020Review
- Tissue-specific relaxin-2 is differentially associated with the presence/size of an arterial aneurysm and the severity of atherosclerotic disease in humans.Acta pharmacologica Sinica · 2020Article
- Pentagalloyl Glucose and Its Functional Role in Vascular Health: Biomechanics and Drug-Delivery Characteristics.Annals of biomedical engineering · 2019Review
- Article
- Associations between serum relaxin 2, aneurysm formation/size and severity of atherosclerosis: a preliminary prospective analysis.Acta pharmacologica Sinica · 2018Article
- A mathematical model of aortic aneurysm formation.PloS one · 2017Article
- An Update on the Inflammatory Response after Endovascular Repair for Abdominal Aortic Aneurysm.Mediators of inflammation · 2015Review
- 18F-fluorodeoxyglucose uptake in abdominal aortic aneurysms: a useful biomarker of AAA rupture risk.BioMed research international · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abdominal aortic aneurysm (AAA) is a prevalent and potentially life-threatening disease. Early detection by screening programs and subsequent surveillance has been shown to be effective at reducing the risk of mortality due to aneurysm rupture. The aim of this review is to summarize the developments in the literature concerning the latest biomarkers (from 2008 to date) and their potential screening and therapeutic values. Our search included human studies in English and found numerous novel biomarkers under research, which were categorized in 6 groups. Most of these studies are either experimental or hampered by their low numbers of patients. We concluded that currently no specific laboratory markers allow screeing for the disease and monitoring its progression or the results of treatment. Further studies and studies in larger patient groups are required in order to validate biomarkers as cost-effective tools in the AAA disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.